Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 5/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | HTT | P42858 | 2/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | APEX1 | P27695 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.46 |
| ▸ | PDE4D | Q08499 | 4/20 | 0.46 |
| ▸ | MYC | P01106 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18785552 | 0.86 | RXRA (0.75) | RXRAALDH1A1MAPTHTTPKM | |
| SCHEMBL18764337 | 0.82 | RXRA (1.00) | RXRAALDH1A1MAPTHTTPKM | |
| SCHEMBL24321967 | 0.72 | RXRA (0.74) | RXRAALDH1A1HTTKDM4EHPGD | |
| SCHEMBL10480847 | 0.70 | AVPR1A (0.66) | RXRAALDH1A1MAPTHTTPKM | |
| SCHEMBL21887690 | 0.67 | NPC1 (0.60) | ALDH1A1KDM4EMEN1HPGDKMT2A | |
| SCHEMBL21760743 | 0.67 | NPC1 (0.60) | ALDH1A1KDM4EMEN1HPGDKMT2A | |
| SCHEMBL4395939 | 0.66 | KDM4E (0.65) | RXRAALDH1A1MAPTKDM4EKMT2A | |
| SCHEMBL3196501 | 0.66 | ALDH1A1 (1.00) | ALDH1A1MAPTHTTPKMKDM4E | |
| SCHEMBL28147295 | 0.65 | ALDH1A1 (0.78) | ALDH1A1MAPTHTTPKMKDM4E | |
| SCHEMBL9939261 | 0.65 | RXRA (0.48) | RXRAALDH1A1MAPTKDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180311243-A1 | NURR1:RXR ACTIVATING COMPOUNDS FOR SIMULTANEOUS TREATMENT OF SYMPTOMS AND PATHOLOGY OF PARKINSON'S DISEASE | VASSILATIS DEMETRIOS K (GR) | 2018-11-01 | — | — | US | claimed |
| EP-3365329-A1 | NURR1:RXR ACTIVATING COMPOUNDS FOR SIMULTANEOUS TREATMENT OF SYMPTOMS AND PATHOLOGY OF PARKINSON'S DISEASE | Vassilatis, Demetrios K. (GR) | 2018-08-29 | — | — | EP | claimed |
| WO-2017068070-A1 | NURR1:RXR ACTIVATING COMPOUNDS FOR SIMULTANEOUS TREATMENT OF SYMPTOMS AND PATHOLOGY OF PARKINSON'S DISEASE | VASSILATIS DEMETRIOS K (GR) | 2017-04-27 | — | — | WO | claimed |
| US-20250152590-A1 | NURR1:RXR ACTIVATING COMPOUNDS FOR SIMULTANEOUS TREATMENT OF SYMPTOMS AND PATHOLOGY OF PARKINSON'S DISEASE | VASSILATIS DEMETRIOS K (GR) | 2025-05-15 | — | — | US | disclosed |
| EP-4029857-A1 | NURR1:RXR ACTIVATING COMPOUNDS FOR SIMULTANEOUS TREATMENT OF SYMPTOMS AND PATHOLOGY OF PARKINSON'S DISEASE | Vassilatis, Demetrios K. (GR) | 2022-07-20 | — | — | EP | disclosed |
| EP-3365329-B1 | NURR1:RXR ACTIVATING COMPOUNDS FOR SIMULTANEOUS TREATMENT OF SYMPTOMS AND PATHOLOGY OF PARKINSON'S DISEASE | VASSILATIS DEMETRIOS K (GR) | 2022-03-30 | — | — | EP | disclosed |
| EP-3365329-B1 | NURR1:RXR ACTIVATING COMPOUNDS FOR SIMULTANEOUS TREATMENT OF SYMPTOMS AND PATHOLOGY OF PARKINSON'S DISEASE | VASSILATIS DEMETRIOS K (GR) | 2022-03-30 | — | — | EP | disclosed |
| US-20210186975-A1 | NURR1:RXR ACTIVATING COMPOUNDS FOR SIMULTANEOUS TREATMENT OF SYMPTOMS AND PATHOLOGY OF PARKINSON'S DISEASE | VASSILATIS DEMETRIOS K (GR) | 2021-06-24 | — | — | US | disclosed |
| US-20210186975-A1 | NURR1:RXR ACTIVATING COMPOUNDS FOR SIMULTANEOUS TREATMENT OF SYMPTOMS AND PATHOLOGY OF PARKINSON'S DISEASE | VASSILATIS DEMETRIOS K (GR) | 2021-06-24 | — | — | US | disclosed |
| US-10946019-B2 | Nurr1:RXR activating compounds for simultaneous treatment of symptoms and pathology of Parkinson's disease | VASSILATIS DEMETRIOS K (GR) | 2021-03-16 | — | — | US | disclosed |
| US-10946019-B2 | Nurr1:RXR activating compounds for simultaneous treatment of symptoms and pathology of Parkinson's disease | VASSILATIS DEMETRIOS K (GR) | 2021-03-16 | — | — | US | disclosed |
| US-20180311243-A1 | NURR1:RXR ACTIVATING COMPOUNDS FOR SIMULTANEOUS TREATMENT OF SYMPTOMS AND PATHOLOGY OF PARKINSON'S DISEASE | VASSILATIS DEMETRIOS K (GR) | 2018-11-01 | — | — | US | disclosed |
| EP-3365329-A1 | NURR1:RXR ACTIVATING COMPOUNDS FOR SIMULTANEOUS TREATMENT OF SYMPTOMS AND PATHOLOGY OF PARKINSON'S DISEASE | Vassilatis, Demetrios K. (GR) | 2018-08-29 | — | — | EP | disclosed |
| WO-2017068070-A1 | NURR1:RXR ACTIVATING COMPOUNDS FOR SIMULTANEOUS TREATMENT OF SYMPTOMS AND PATHOLOGY OF PARKINSON'S DISEASE | VASSILATIS DEMETRIOS K (GR) | 2017-04-27 | — | — | WO | disclosed |
| WO-2017068070-A1 | NURR1:RXR ACTIVATING COMPOUNDS FOR SIMULTANEOUS TREATMENT OF SYMPTOMS AND PATHOLOGY OF PARKINSON'S DISEASE | VASSILATIS DEMETRIOS K (GR) | 2017-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250152590-A1 | NURR1:RXR ACTIVATING COMPOUNDS FOR SIMULTANEOUS TREATMENT OF SYMPTOMS AND PATHOLOGY OF PARKINSON'S DISEASE | NR4A2, NR0B1, NCOR1 | RXRA 7/4885ALDH1A1 1790/4885MAPT 2428/4885 |
| US-20210186975-A1 | NURR1:RXR ACTIVATING COMPOUNDS FOR SIMULTANEOUS TREATMENT OF SYMPTOMS AND PATHOLOGY OF PARKINSON'S DISEASE | NR4A2, NR0B1, NR4A3 | RXRA 7/4885ALDH1A1 1716/4885MAPT 2436/4885 |
| US-10946019-B2 | Nurr1:RXR activating compounds for simultaneous treatment of symptoms and pathology of Parkinson's disease | NR4A2, NR0B1, NR4A3 | RXRA 7/4885ALDH1A1 1716/4885MAPT 2436/4885 |
| US-20180311243-A1 | NURR1:RXR ACTIVATING COMPOUNDS FOR SIMULTANEOUS TREATMENT OF SYMPTOMS AND PATHOLOGY OF PARKINSON'S DISEASE | NR4A2, NR0B1, NR4A3 | RXRA 7/4885ALDH1A1 1716/4885MAPT 2436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.